All Stories

  1. Cancer treatments: Past, present, and future
  2. Improving transparency of computational tools for variant effect prediction
  3. Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
  4. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)
  5. TP53 isoform junction reads based analysis in malignant and normal contexts
  6. MutSpliceDB: A database of splice sites variants with RNA‐seq based evidence on effects on splicing
  7. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets
  8. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
  9. Standard operating procedure for curation and clinical interpretation of variants in cancer
  10. Early Detection is as Important as Imatinib in CML Treatment Success
  11. Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?
  12. Bioinformatics Tools and Resources for Cancer Immunotherapy Study
  13. Next-generation characterization of the Cancer Cell Line Encyclopedia
  14. Neuroendocrine negative SCLC is mostly RB1 WT and may be sensitive to CDK4/6 inhibition: Supplemental Tables
  15. Adapting crowdsourced clinical cancer curation in CIViC to the ClinGen minimum variant level data community‐driven standards
  16. Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes
  17. ClinGen Cancer Somatic Working Group – standardizing and democratizing access to cancer molecular diagnostic data to drive translational research
  18. Detection of homozygous deletions in tumor-suppressor genes ranging from dozen to hundreds nucleotides in cancer models
  19. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
  20. Somatic cancer variant curation and harmonization through consensus minimum variant level data
  21. TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
  22. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
  23. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity
  24. Pharmacogenomic agreement between two cancer cell line data sets
  25. Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
  26. The identification and characterization of a STAT5 gene signature in hematologic malignancies
  27. Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling
  28. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
  29. Tumor Suppressors Status in Cancer Cell Line Encyclopedia
  30. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
  31. Maintenance of adenomatous polyposis coli ( APC )-mutant colorectal cancer is dependent on Wnt/β-catenin signaling
  32. Genetic Mechanisms in Apc-Mediated Mammary Tumorigenesis
  33. Loss of Rb1 in the gastrointestinal tract of Apc 1638N mice promotes tumors of the cecum and proximal colon